

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739

Date: 26 May 2025

To Corporate Relationship Department BSE Limited, 1st Floor, Rotunda Building, P.J. Towers, Dalal Street, Mumbai – 400 001. To National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) Mumbai – 400 051.

Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED

Dear Sir/Madam,

Sub: Investor Presentation of the Company for the quarter & year ended 31 March 2025
 Ref: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
 Regulations, 2015

With reference to the captioned subject, the Investor Presentation for the quarter and year ended 31 March 2025, on Company Overview, Business highlights, financial performance and other updates is enclosed herewith for your consideration.

We request you to take the same on record.

A copy of this intimation is also being made available at:

https://vbshilpa.com/investor-presentation.php

Thanking you

For Shilpa Medicare Limited,

Ritu Tiwary Company Secretary & Compliance Officer



Shilpa Medicare Ltd

4QFY25 Earnings Presentation

Date: 26th May 2025



Safe Harbour





Certain statements in this document may be forward - looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Shilpa Medicare Limited (SML) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Shilpa Medicare at a glance



Ľ⊘

÷



} \r } -----

Worldwide presence in **50+** countries

FY25 Financials

Revenue INR 1,310 crores (+13% YoY) EBITDA INR 340 crores (+35% YoY)





Existing Business Segments: API, Formulation, CDMO, Biologics

Emerging Businesses: NDDS, ADC and Recombinant Human Albumin

10+ Regulatory approved manufacturing + R&D facilities (incl Analytical Lab)

400+ R&D Personnel

500+ Regulatory Filings across the world

Company snapshot





- The business comprises of production of APIs (oncology and non- oncology), Peptides, Polymers and intermediates.
- With a focus on introducing generic molecules that face entry barriers, Specialization in complex API processes for both oncology and nononcology molecules



- Differentiated portfolio of Onco and Non- Onco products including 505 (b)(2) with focus on ease of administration for patients.
- We Develop, manufacture & License of a wide range of products, including oral solids, liquid injections, dry powder injectable products, orally disintegrating films (ODFs), transdermal patches and lyophilised injectables





- Offering Biosimilar portfolio across niche therapies such as Oncology, immunotherapy, and Ophthalmology
- End-to-end biologics CDMO services for drug substances (mammalian and microbial) and drug products
- "Clone-to-vial" capabilities make Shilpa Biologicals the preferred one-stop outsourcing partner.
- Strong capabilities to manufacture ADCs and GLP-1 products

FY25 Revenue – INR 75 crs



CDMO

- Integrated, one stop CMC solutions for development and manufacturing of preclinical, clinical and commercial
- Capabilities include developing & Manufacturing DS and DP for Small Molecules and complex chemistries.
- Servicing to various global biotech companies including 10+ big pharma clients
- Ready capacities available for large molecule CDMO biologics

FY25 Revenue – INR 158 crs*

sRbumin

Recombinant Albumin

- Developed & patented a novel rHA (recombinant Human Albumin) process which is
 - Environment friendly
 - Highly scalable
 - High-Quality consistency
 - Cost competitive


Pre revenue stage

FY25 Revenue – INR 736 crs



Key operating verticals





Management Commentary





FY25 performance reflects our pursuit of differentiated business model enabling us to grow with improved profitability.

In FY25, Shilpa Medicare has emerged stronger, turning years of strategic investments and relentless perseverance into remarkable achievements in differentiated initiatives like launch of two NDAs in US market, filing of transdermal patch product in EU, SEC clearance of Nor-UDCA in India and OLC filing by our partner with US FDA. Our unwavering commitment to innovation and R&D has borne fruit, with significant breakthrough in out licensing our flagship product – Recombinant Human Albumin, for commercialization across EU region in strategic partnership with Orion Corporation.

Besides this, we also saw a very successful year on the regulatory front, as we received EIR for our API unit 1, along with EU GMP certifications for our FDF Unit 6 (having ODF & TDP manufacturing capabilities) and for our Biologics unit. I believe this will help in enabling us to further scale up our Biologics CDMO platform and give us the opportunity to monetize our Biosimilar pipeline for large regulated markets.

With asset utilization improvement across key verticals, we remain confident of delivering improved profitability in FY26. As we advance, we remain committed to leveraging our R&D strengths, regulatory compliance, and operational agility to create long-term value.

- Mr. Vishnukant Bhutada Managing Director



4QFY25 Performance

4Q FY25 – Financial Performance



4Q FY25 (Consolidated)					
Particulars (INR cr)	4QFY25	4QFY24	ΥοΥ	3QFY25	QoQ
Total Revenue	338	294	15%	320	6%
Gross Profit	234	197	19%	229	2%
GP Margin	69%	67%	200 bps	72%	-300 bps
EBITDA	84	73	15%	82	2%
EBITDA Margin	25%	25%	-	26%	-100 bps
Adjusted PAT*	33	20	65%	32	3%
PAT Margin	10%	7%	300 bps	10%	-

Revenue Break-up (INR in cr.)

Result commentary

- Revenue grew by 15% on YoY basis, driven by healthy performance in our fast-growing FDF vertical
- Gross margins for the quarter came in at 69%, improving 200 bps YoY
 - Gross margins improved despite lower Licensing income and lower CDMO revenue on YoY basis
- EBITDA grew by 15% YoY at INR 84crs; EBITDA Margins at 25%
- Exceptional item consists of settlement with Celltrion INC amounting to ~INR 29crs
- *Adjusted to Exceptional Item (net of tax), PAT stood at INR 33crs which showed an increase of ~65% YoY


All numbers are rounded off to nearest one

FY25 – Financial Performance



FY25 (Consolidated)			
Particulars (INR cr)	FY25	FY24	YoY (%)
Total Revenue	1,310	1,160	13%
Gross Profit	899	752	20%
GP Margin	69%	65%	400bps
EBITDA	340	253	35%
EBITDA Margin	26%	22%	400bps
Adjusted PAT*	97	28	246%
PAT Margin	7%	2%	500bps

Revenue Break-up (INR in cr.)



Result commentary


- Revenue grew by 13% on a YoY basis, driven by healthy performance across our key verticals viz. FDF & Biologics
- Gross margins continue to improve at 69%, driven by better product mix
- EBITDA for FY25 stood at INR 340crs higher by 35% YoY; EBITDA Margins at ~26%
- Exceptional item consist of settlement with Celltrion INC amounting to ~INR 29crs
- *Adjusted to Exceptional Item (net of tax), PAT stood at INR 97crs which has grown over 2x YoY

All numbers are rounded off to nearest one


Consolidated Performance




(INR in Cr.)



EBITDA and Margins 26% 26% 25% 25% 340 253 22% 84 73 82 FY25 4QFY24 3QFY25 4QFY25 FY24








*4Q & FY25 PBT & PAT are adjusted to Exceptional item consisting of settlement with Celltrion INC amounting to ~INR 29crs


Financial Summary














API Business

API – Muted growth; order book remains healthy





(INR in Cr.)

- 4QFY25 Revenue growth was driven by portfolio rationalization and improved offtake of key products, coupled with contribution from newly increased capacities for key products
- Completed capacity expansion for key products viz. UDCA, Tranexamic Acid, Azacitidine, Palbociclib and Nilotinib. To drive incremental growth from FY26 onwards
- Rationalizing portfolio towards higher margin product and markets. Expanding product portfolio with launches in multiple complex APIs and Specialty portfolio
- Added new clients in various geographies

API – Ongoing Developments



API Molecules


- Commercialized Increased capacities for key products viz. UDCA, Tranexamic Acid and Onco molecules
- Initiated validation for 4 new products
- Received CEP from EDQM for Teriflunomide

CDMO

- Added 2 new customers, taking the total count to 20+
- Successfully Completed Phase II supply for a multi-step complex chemistry project, offering One-Stop-Solution for drug substance and drug product development for US client.
- In our ongoing NDA program, where we serve as our partner's CDMO, secured FDA's clearance to conduct Ph2 trials for additional indication and subsequently partner has received fast track designation
- New dedicated block for OLC expected to be commercialized in FY26
- Increase in number of RFQs received from various global biotech

Polymer and Peptide

- Commercial manufacturing started of large polymer project worth ~USD 4mn received from a US MNC for non pharma applications. Sole supplier from India, with order value expected to increase going forward.
- Developed a process for synthesizing polymer with varying molecular weights, widely used in biomedical applications, including drug delivery and tissue engineering
- GLP 1 Liraglutide dossier filing and Semaglutide plant scaleup planned in 1QFY26
- Initiated commercial batch scale up for CEP approved peptide APIs




Unit 2 audit with US FDA was completed with Zero observations, EIR awaited



Formulations Business

New product launches drive FDF revenue growth





(INR in Cr.)

- For the quarter, the division reported robust revenue growth of 38% on YoY basis
- Launched our 2nd NDA viz.
 Bortezomib RTU Subcutaneous in US, scale up expected in FY26.
- Received EU approval for Tadalafil ODF in EU region.
 Received approval for Varenicline tablets for US market
- Nilotinib drove strong growth in EU region
- All 3 approved NDAs have limited competition. More NDAs will be filed in coming quarters
- Submitted remediation work with the US FDA for re-inspection of Jadcherla Unit


FDF – Update on key assets



NorUDCA SMLNUD07	SMLTDP08	SMLTOP09	SMLODF010	SMLINJ011	ODF & TDS
 CDSCO approved Ph3 clinical trials and recommended for market authorization approval, Launch planned in 1HFY26 The product will be first NCE launch for NAFLD disease treatment for company 	 Transdermal Patch for treatment of Parkinson's disease US Study initiated in 4QFY25 Europe submission completed in 2Q FY25 by our partner and expecting a limited competition launch in FY26 	 Topical lotion for treatment of Androgenic Alopecia Phase II completed, and data submitted to Indian regulatory body; Phase III study to start post approval EU Scientific advice filed 	 Expected to launch in European market in FY26 	 Injection for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, radiotherapy and other associated medication. Market Size is ~\$931 mn (Global)* Initiated Ph3 clinical studies in India Responses received from scientific advises filed in EU and US Pre IND; basis of response further studies are planned 	 Two new transdermal patch product development completed. Initiated pilot study for One product in EU market and planned studies for another product in 1HFY26 The product is complex and uniquely positioned with no generic competition Tadalafil ODF approved in EU market, launch expected in FY26

Filings – Formulations





Robust regulatory filings to strengthen the base for growth in the formulation segment Our ODF & TDP manufacturing Unit 6 received GMP approval from EMA (European Medicines Agency)



CDMO Business

CDMO – Strong capabilities in various technologies




			Very strong capability	Strong ca	pability Devel	oping capability	Negligible capability
	•		Indian CDMOs —	• •		Global CDMOs	Global CDMOs
	Shilpa Medicare	Peer 1	Peer 2	Peer 3	Global Peer 1	Global Peer 2	Global Peer 3
Specialized technologies							
Small molecule							
Peptide							
Monoclonal Antibodies and Recombinant technology							
Antibody – Drug conjugates							
Fermentation							
Offerings							
Development							
Manufacturing							

- Early phase to late phase from AI/ML led discovery (target to hit, hit to lead and lead to NCE) to custom synthesis, scale up and clinical materials (for advanced intermediates, RSMs
- "Clone-to-vial" capabilities makes us a preferred one-stop outsourcing partner, securing strong market position
- Leveraging expertise to offer interconnected tech platform for various fast growing opportunities in the areas of fermentation, Antibody-Drug Conjugates (ADCs), and GLP-1
- Leveraging exquisite strengths in complex chemistry across pharma and specialty chemicals. Integrated CMC approach for delivering drug substance and drug product to pharma customers

Robust business model encompassing various stages





Comprehensive CDMO Development



Unicycive Therapeutics Inc's Oxylanthanum Carbonate (OLC) is a Potential best-in-class product being developed under FDA's 505(b)(2) regulatory pathway for the treatment of hyperphosphatemia



NDA accepted by the US FDA with potential approval FY26

Long term manufacturing and supply agreement with SML.



SML is receiving significant milestone income spanning over various stages viz. filing, approval and launch of the product



| Innovating for | affordable healthcare

Building back-end to develop & manufacture both API & Formulation

Product Profile¹

- Potential best-in-class product for the treatment of Hyperphosphatemia
- Advantages: (1) Potency: Shares high phosphate binding capacity of lanthanum; (2) Pill Burden: Smaller and fewer pills; (3) Palatability: swallowed whole with water and not chewed
- A comprehensive CDMO contract for both API and formulation development – a One-stop-Solution
- Unicycive announced successful trial results and FDA acceptance of its New Drug Application for OLC, with PDUFA June 28, 2025, potentially easing treatment for hyperphosphatemia in CKD dialysis patients.



Biologics & NBE


Biologics – Growth envisioned on 4 pillars



 Adalimumab: India market to grow 2x in FY26 based on approval of additional indications (Crohn's disease and Ulcerative colitis in adults). Filing in progress in 15 RoW markets, with approvals expected in FY26 Aflibercept: Ophthalmic biologic with a global market size of ~USD 9 bn¹ initiated into Ph3 with expected launch in FY26. Out-licensed to two partners in India and Russia, with multiple discussions in MENA region Novel MAB (oncology): Term sheet signed with mABTree. Expecting Cell line in 1HFY26 and targeting for investigator led trials in late FY26 Signed 1 large microbial-based project with long term manufacturing contract Signed 1 mammalian-based project I New project in food sector signed in Dec 2024 Building bioconjugation suite for Drug Substance Leveraging our Leveraging our 	Biologics	Novel Biologics	Integrated CDMO @Dharwad	Other Key updates
	 2x in FY26 based on approval of additional indications (Crohn's disease and Ulcerative colitis in adults). Filing in progress in 15 RoW markets, with approvals expected in FY26 Aflibercept: Ophthalmic biologic with a global market size of ~USD 9 bn¹ initiated into Ph3 with expected launch in FY26. Out-licensed to two partners in India and Russia, with multiple discussions in MENA region Nivolumab (USD 10 bn)¹, Pembrolizumab (USD 30 bn)¹ small scale development completed and PCT initiated. Clinical initiation targeted in FY26 Daratumumab (USD 6 bn)¹ and Dupilumab (USD 16 bn)¹ cell line development initiated, PCT in FY26 Trastuzumab (USD 4 bn)¹ process 	sheet signed with mABTree. Expecting Cell line in 1HFY26 and targeting for investigator led trials	 pharmaceutical segment are ongoing Signed 1 large microbial-based project with long term manufacturing contract Signed 1 mammalian-based project 1 New project in food sector signed in Dec 2024 Extensive BD efforts are planned for expanding business in this segment Increase in number of RFQs received from various global 	 received EU GMP approval Received GMP certification approval from Oman MoH In process of building differentiated capacities in ADCs Building bioconjugation suite for Drug Substance Leveraging our HpAPI for Linker and Payload Leveraging our formulations site for fill


Why Recombinant Human Albumin?





Shilpa's Recombinant Human Albumin





Outlook FY26 and beyond





FDF 6 key products (NDA-Pemetrexed, NDA – Bortezomib, Nilotinib, Axitinib, Rotigotine and NorUDCA) launches/Scale up to drive revenue materially

CDMO

Commercial launch of OLC in US

to kick start significant revenue

Other late-stage assets

progressing well



API Multiple complex API launches, growth in Specialty portfolio, coupled with capacity expansion for existing key products to drive API growth



Biologics

Strong Biosimilar pipeline with various large assets completing clinical trails, coupled with niche CDMO Biologic offerings to drive Biosimilar revenue growth in significant manner from late FY26



Recombinant Albumin Ph3 trials for India to start in FY26. Strategic tie up with Orion Corporation. Non – therapeutic usage is being explored



Licensing income Various assets where licensing income was received are moving towards commercial long term supply agreements



Impending Operating Leverage Substantial portion of current gross block remains under utilized having spread across high margin divisions viz. Biosimilar, CDMO and NDDS



Margin Improvement Improved utilization is likely to drive meaningful improvement in revenue and EBITDA margins

Manufacturing Capabilities – API & Biocare





Manufacturing Capabilities – Formulations & Biologics







Financials

Profit & Loss Consolidated



Particulars (INR cr)	4Q FY25	4Q FY24	<i>ΥοΥ</i>	3Q FY25	QoQ	FY25	FY24	<u> Υο</u> Υ
Revenues	338	294	15%	320	6%	1,310	1,160	13%
Gross Profit	234	197	19%	230	2%	899	752	20%
Gross Margin %	69%	67%		72%		69%	65%	
Employee Cost	71	66	7%	74	-4%	293	282	4%
Other Expenses	79	58	36%	74	7%	266	218	22%
EBITDA	84	73	15%	82	2%	340	253	35%
EBITDA Margin %	25%	25%		26%		26%	22%	
Finance Cost	15	24	-38%	12	25%	76	92	-17%
Depreciation	29	27	7%	29	-	113	108	5%
Adj PBT*	43	22	95%	42	2%	150	48	212%
Adj PAT*	33	20	65%	32	3%	97	28	246%

*4Q & FY25 PBT & PAT are adjusted to Exceptional item consisting of settlement with Celltrion INC amounting to ~INR 29crs

Balance Sheet Consolidated



Particulars (INR crs)	31-Mar-25	31-Dec-24	31-Mar-24
Fixed Assets	1,418	1,425	1,385
 Tangible Assets 	1,212	1,214	1,193
 Intangible Assets 	205	211	192
Capital WIP	822	754	719
 Tangible Assets 	463	423	403
 Intangible Assets 	359	332	316
Other Non-current Assets	73	109	103
Net Working Capital	666	647	558
 Current Assets 	957	899	845
 Cash and cash equivalents 	29	19	32
 Current Liabilities 	-320	-270	-318
Total Assets (Net)	2,978	2,935	2,765
 Equity 	2,364	2,352	1,800
 Borrowings (Current & Non-current) 	586	549	936
 Other Non-Current Liabilities 	28	34	29
Total Liabilities	2,978	2,935	2,765

Earnings call Details



Shilpa Medicare 4QFY25 Results Conference Call to be held May 26, 2025, Monday at 17:00

Details of Earnings Conference Ca	all
Universal Access	+91 22 6280 1130 +91 22 7115 8031
The number listed above is univer	sally accessible from all networks and all countries
International Toll-Free Numbers	
USA UK Singapore Hong Kong	18667462133 08081011573 8001012045 800964448
DiamondPass [™] Link	<u>Click here</u> to join with DiamondPass [™] (No Wait Time)



Shilpa Medicare LimitedImage: Monish ShahImage: Height of the stateImage: Height of

Ernst & Young IR



Runjhun Jain/Sneha Salian



+91 98207 20993 / +91 98194 30437



runjhun.jain1@in.ey.com / sneha2.salian@in.ey.com

THANK YOU!